Vitiligo PSP completed in 2010	l	Million In Alexand	Mile - 1 1 -	Millelack damage of		Mile I - In to me	0	Online and successful to	Defense of a sellable on to 1	Our term at la	0		Whiteh and a second
Indicative Uncertainty		Why is there uncertainty?	What is person's age?	Which types of treatments? 1	Which types of treatments? 2	Which types of treatments? 3	Source	Original uncertainty	References to reliable up-to-date systematic reviews	Systematic reviews in preparation	Systematic reviews that need updating or extending	Ongoing controlled trials	Which outcomes?
Are calcineurin inhibitors (tacrolimus or pimecrolimus) effective in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for vililigo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD0032E3. DOI: 10.1002/14651858.CD0032E3.pub4			Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis) NCT01082393	Quality of life' measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin'; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
Are calcineurin inhibitors (tacrolimus		Reliable up-to-date	Any age	Drug			Setting Priorities and		Whitton ME, Pinart M, Batchelor J,				Quality of life* measured using a validated
or pimecrolimus) more effective if used to treat villigo when it first appears, rather than waiting until the disease has spread?	identified from patients' questions	systematic reviews have revealed important continuing uncertainties about treatment effects					Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Childrens Dermatology Quality of Life Index), Skindex-29: Percentage of repigmentation of vitiliginous sitah"; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
Are calcineurin inhibitors (tacrolimus or pimecrolimus) more effective in treading vitiligo when combined with steroid creams?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for vililigo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life' measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vililiginous skin'; cessation of spread of vililigo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
Are creams and ointments (e.g. steroid creams) more effective when combined with natural sunlight?	Uncertainties identified in research recommendations	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Environmental	Drug		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for vililigo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of Ilife' measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin'; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects 'Primary outcomes
Are moisturisers effective in stopping the spread of vitiligo?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for Villigo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4				Quality of life' measured using a validated tool e.g. DLQi (Dermatology Quality of Life Index), CDLQi (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vililiginous skin'; cessation of spread of vililigo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects 'Primary outcomes
Are steroid creams more effective if used to treat vitiligo when it first appears, rather than waiting until the disease has spread?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonard-Bee J, Gonz?lez U, Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD0032E3. DOI: 10.1002/14651858.CD0032E3.pub4				Quality of life' measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vililiginous skin'; cessation of spread of vililigo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes

associated with steroid cream in				1-		1				
	Uncertainties	Reliable up-to-date	Any age	Drug		Setting Priorities and	Whitton ME, Pinart M, Batchelor J,			Side effectsVitiligo and the Koebner
treatments?	identified from	systematic reviews				Reducing	Lushey C, Leonardi-Bee J, Gonz?lez U.			Phenomenon (Model of Vitiligo Induction
	patients' questions	have revealed				Uncertainties for the	Interventions for vitiligo. Cochrane			and Therapy: a Clinical and Immunological
		important continuing				Prevention and	Database of Systematic Reviews 2010,			Analysis) NCT01082393
		uncertainties about				Treatment of Skin	Issue 1. Art. No.: CD003263. DOI:			
		treatment effects				Disease (SPRUSD)	10.1002/14651858.CD003263.pub4			
						0				
	Uncertainties		Any age	Unclassified		Setting Priorities and	Whitton ME, Pinart M, Batchelor J,			Risks, safety and side effects
	identified from	systematic reviews				Reducing	Lushey C, Leonardi-Bee J, Gonz?lez U.			
F	patients' questions	have revealed				Uncertainties for the	Interventions for vitiligo. Cochrane			
		important continuing				Prevention and	Database of Systematic Reviews 2010,			
		uncertainties about				Treatment of Skin	Issue 1. Art. No.: CD003263. DOI:			
		treatment effects				Disease (SPRUSD)	10.1002/14651858.CD003263.pub4			
Are there any side effects associated U	Uncertainties	Reliable up-to-date	Any age	Unclassified		Setting Priorities and	Whitton ME, Pinart M, Batchelor J,			Side effects
	identified from	systematic reviews	2.01			Reducing	Lushey C, Leonardi-Bee J, Gonz?lez U.			
	patients' questions	have revealed				Uncertainties for the	Interventions for vitiligo. Cochrane			
management of vitiligo?		important continuing				Prevention and	Database of Systematic Reviews 2010,			
		uncertainties about				Treatment of Skin	Issue 1. Art. No.: CD003263. DOI:			
		treatment effects				Disease (SPRUSD)	10.1002/14651858.CD003263.pub4			
										0.1. //
	Uncertainties	Reliable up-to-date	Any age	Drug	1 1	Setting Priorities and	Whitton ME, Pinart M, Batchelor J,		Vitiligo and the Koebner Phenomenon	Side effects
	identified from	systematic reviews	l l	1	1 1	Reducing	Lushey C, Leonardi-Bee J, Gonz?lez U.		(Model of Vitiligo Induction and	
	patients' questions	have revealed	I	1	1 1	Uncertainties for the	Interventions for vitiligo. Cochrane	ļ	Therapy: a Clinical and	
vitiligo?		important continuing	1	1	1	Prevention and	Database of Systematic Reviews 2010,	1	Immunological Analysis)	
I		uncertainties about	I	1	1 1	Treatment of Skin	Issue 1. Art. No.: CD003263. DOI:		NCT01082394	
I		treatment effects				Disease (SPRUSD)	10.1002/14651858.CD003263.pub4			
Are there any side effects associated L	Uncertainties	Reliable up-to-date	Any age	Physical		Setting Priorities and	Whitton ME, Pinart M, Batchelor J,			Side effects
	identified from	systematic reviews	,	therapies		Reducing	Lushey C, Leonardi-Bee J, Gonz?lez U.	1	1	
	patients' questions	have revealed		tricrapics		Uncertainties for the	Interventions for vitiligo. Cochrane			
cream to treat vitiligo?	patients questions	important continuing				Prevention and	Database of Systematic Reviews 2010,			
		uncertainties about				Treatment of Skin	Issue 1. Art. No.: CD003263, DOI:			
		treatment effects				Disease (SPRUSD)	10.1002/14651858.CD003263.pub4			
		treatment encors				Discuse (OF TOOD)	10.1002/14031030.00003203.0004			
	Uncertainties	Reliable up-to-date	Any age	Drug	Devices	Setting Priorities and	Whitton ME, Pinart M, Batchelor J,			Side effects
	identified from	systematic reviews				Reducing	Lushey C, Leonardi-Bee J, Gonz?lez U.			
	patients' questions					Uncertainties for the	Interventions for vitiligo. Cochrane			
treating vitiligo?		important continuing				Prevention and	Database of Systematic Reviews 2010,			
		uncertainties about				Treatment of Skin	Issue 1. Art. No.: CD003263. DOI:			
		treatment effects				Disease (SPRUSD)	10.1002/14651858.CD003263.pub4			
Are there any side effects associated U	Uncertainties	Reliable up-to-date	Any age	Drug		Setting Priorities and	Whitton ME, Pinart M, Batchelor J,		Vitiligo and the Koebner Phenomenon	Side effects
	identified from	systematic reviews	Any age	Diug		Reducing	Lushey C, Leonardi-Bee J, Gonz?lez U.		(Model of Vitiligo Induction and	
	patients' questions	have revealed				Uncertainties for the	Interventions for vitiligo. Cochrane		Therapy: a Clinical and	
viaigo:	patients questions	important continuing				Prevention and	Database of Systematic Reviews 2010,		Immunological Analysis)	
		uncertainties about				Treatment of Skin	Issue 1. Art. No.: CD003263. DOI:		NCT01082393	
		treatment effects				Disease (SPRUSD)	10.1002/14651858.CD003263.pub4		10101002000	
						. ,				
	Uncertainties		Any age	Physical		Setting Priorities and	Whitton ME, Pinart M, Batchelor J,			Side effects
	identified from	systematic reviews	I	therapies	1 1	Reducing	Lushey C, Leonardi-Bee J, Gonz?lez U.	ļ		
treating vitiligo?	patients' questions	have revealed				Uncertainties for the	Interventions for vitiligo. Cochrane			
		important continuing				Prevention and	Database of Systematic Reviews 2010,			
		uncertainties about				Treatment of Skin	Issue 1. Art. No.: CD003263. DOI:			
		treatment effects				Disease (SPRUSD)	10.1002/14651858.CD003263.pub4			
Are there any side effects associated U	Uncertainties	Reliable up-to-date	Any age	Physical		Setting Priorities and	Whitton ME, Pinart M, Batchelor J,			Side effects
	identified from	systematic reviews	,	therapies	1 1	Reducing	Lushey C, Leonardi-Bee J, Gonz?lez U.	ļ		
with UVB light therapy in treating	patients' questions	have revealed	1		1	Uncertainties for the	Interventions for vitiligo. Cochrane	1	1	
		important continuing	I	1	1 1	Prevention and	Database of Systematic Reviews 2010,			
		uncertainties about	I	1	1 1	Treatment of Skin	Issue 1. Art. No.: CD003263. DOI:	ļ		
		treatment effects				Disease (SPRUSD)	10.1002/14651858.CD003263.pub4			
				1	1 1					
vitiligo?						Setting Priorities and	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U.			Quality of life* measured using a validated
vitiligo? F	Uncertainties	Reliable up-to-date	Any age	Mixed or						
vitiligo? F Are Vitamin D analogues (calcipotriol L and tacalcitol) more effective in ii	identified in	systematic reviews	Any age	Mixed or complex		Reducing				tool e.g. DLQI (Dermatology Quality of Life
vitiligo? F Are Vitamin D analogues (calcipotriol U and tacalcitol) more effective in i treating vitiligo when combined with r	identified in research	systematic reviews have revealed	Any age			Reducing Uncertainties for the	Interventions for vitiligo. Cochrane			Index), CDLQI (Children's Dermatology
vitiligo? F Are Vitamin D analogues (calcipotriol U and tacalcitol) more effective in i treating vitiligo when combined with r	identified in	systematic reviews have revealed important continuing	Any age			Reducing Uncertainties for the Prevention and	Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010,			Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29;
vitiligo? F Are Vitamin D analogues (calcipotriol U and tacalcitol) more effective in i treating vitiligo when combined with r	identified in research	systematic reviews have revealed important continuing uncertainties about	Any age			Reducing Uncertainties for the Prevention and Treatment of Skin	Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI:			Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous
vitiligo? F Are Vitamin D analogues (calcipotriol U and tacalcitol) more effective in i treating vitiligo when combined with r	identified in research	systematic reviews have revealed important continuing	Any age			Reducing Uncertainties for the Prevention and	Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010,			Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or
vitiligo? F Are Vitamin D analogues (calcipotriol U and tacalcitol) more effective in i treating vitiligo when combined with r	identified in research	systematic reviews have revealed important continuing uncertainties about	Any age			Reducing Uncertainties for the Prevention and Treatment of Skin	Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI:			Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long-
vitiligo? F Are Vitamin D analogues (calcipotriol U and tacalcitol) more effective in i treating vitiligo when combined with r	identified in research	systematic reviews have revealed important continuing uncertainties about	Any age			Reducing Uncertainties for the Prevention and Treatment of Skin	Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI:			Index), CDLQI (Children's Dermatology Quality of Life Index,) Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation
vitiligo? F Are Vitamin D analogues (calcipotriol U and tacalcitol) more effective in i treating vitiligo when combined with r	identified in research	systematic reviews have revealed important continuing uncertainties about	Any age			Reducing Uncertainties for the Prevention and Treatment of Skin	Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI:			Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of regigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years
vitiligo? F Are Vitamin D analogues (calcipotriol U and tacalcitol) more effective in i treating vitiligo when combined with r	identified in research	systematic reviews have revealed important continuing uncertainties about	Any age			Reducing Uncertainties for the Prevention and Treatment of Skin	Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI:			Index), CDLOI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation

steroid creams?	identified from clinicians' questions	systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for villigo. Cochrane Database of Systematic Reviews 2010, Issue 1 Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life* measured using a validated tool e.g. DLGI (Dermatology Quality of Life Index), CDLDI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*, cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up), adverse effects 'Primary outcomes
Does the addition of psychological interventions (e.g. counselling, support) to patients receiving cosmetic camouflage improve their quality of life?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Psychological therapy		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Ranked 9; Patient rank 6, HP 6	Whitton ME, Pinart M, Batchelor J, Lushey C, Leorardi-Bee J, Gorz/lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life* measured using a validated tool e.g. DLQ (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*, cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
Does treatment with immunosuppressants help patients with vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonzrdi-Bee J, Gonz/lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1 Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life* measured using a validated tool e.g. DLQ (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitilignous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex	Environmental	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz'lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4		repigmentation
How effective are anti-oxidants when combined with mitochondrial stimulating cream in treating vitiligo?	Uncertainties identified in research recommendations	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz'lez U, Interventions for villigo. Cochrane Database of Systematic Reviews 2010, Issue 1 Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
How effective are anti-oxidants when combined with tablets such as phenylalanine in treating vitiligo?	Uncertainties identified in research recommendations	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for villigo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CC003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*, cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up), adverse effects "Primary outcomes
How effective are herbal remedies in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Complementary therapies		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1 Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life' measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin'; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes

How effective are hormones or hormone related substances that stimulate pigment cells (NSH analogues, afamelanotide) in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Ranked 6; Patient rank 8, HP 16	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for Villigo. Cochrane Database of Systematic Reviews 2010. Issue 1. Art. Noc. CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*: cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective are other complementary therapies (e.g. aloe vera, UNANI) in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Complementary therapies	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4	Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo NCT01006421	Quality of life* measured using a validated tool e.g. DLQI (Cernatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
How effective are SAD light boxes in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Physical therapies	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchefor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life' measured using a validated tool e.g. DLQI (Dermatology Quality of Life lindex), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitilignous skin'; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
How effective are steroid creams in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4	Vfitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis). NCT01082393	Quality of life' measured using a validated tool e.g. DLQI (Dermatology Quality of Life lindex), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitilignous skin'; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
How effective are steroid tablets in treating vitiligo?	Uncertainties identified from patients' questions	systematic reviews	Any age	Drug	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for villigo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life' measured using a validated tool e.g. DLQI (Dematology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin'; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up; adverse effects "Primary outcomes
How effective is cosmetic camouflage for the management of vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Physical therapies	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life' measured using a validated tool e.g. DLQI (Dermatology Quality of Life lindex), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitilignous skin'; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes

How effective is education into the use of cosmetic camouflage for the	patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects Reliable up-to-date systematic reviews	Any age Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD) Setting Priorities and Reducing	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for Vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life' measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage or repigmentation of vitiliginous skin'; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes Quality of life' measured using a validated tool e.g. DLQI (Dermatology Quality of Life
management of vitiligo?	patients' questions	have revealed important continuing uncertainties about treatment effects					Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Index), CDLQI (Children's Dermatology Quality of Lie Index), Skindex-29: Percentage of repigmentation of vitiliginous skin'; cessation of spread of vitilig or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
How effective is hormone replacement therapy (HRT) in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonzdri-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1 Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life* measured using a validated tool e.g. DLQ (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitilignous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects 'Primary outcomes
How effective is laser therapy in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Physical therapies	Devices		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonzdri-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, ISsue 1 Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life* measured using a validated tool e.g. DLO (Bermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects 'Primary outcomes
How effective is laser therapy when combined with creams or ointments (e.g. steroid cream) in treating vitiligo?	Uncertainties identified in research recommendations	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug	Devices	Physical therapies	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for villigo. Cochrane Database of Systematic Reviews 2010, ISsue 1 Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life* measured using a validated tool e.g. DLOI (Dermatology Quality of Life Index), CDLOI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitilgo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
How effective is levamisole in treating vitiligo?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1 Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Duality of life* measured using a validated tool e.g. DL() (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitilignous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects 'Primary outcomes

mouth when combined with creams or ointments (e.g. steroid cream) in treating vitiligo?	Uncertainties identified in research recommendations	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonz/des U, Gonz/lez U, Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1 Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life' measured using a validated tool e.g. DLQI (Dematology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin'; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Complementary therapies	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonz/lea U, Loncy/lea U, Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1 Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life' measured using a validated tool e.g. DLQI (Chrintarology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin'; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Surgery	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz'lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. Noc. CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of IIIe' measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; eessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
achieving repigmentation of the skin	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Environmental	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz'lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. Noc. CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of IIIe' measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; eessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Physical therapies	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchefor J, Lushey C, Leonardi-Bee J, Gonz'lez U, Interventions for villigo. Cochrane Database of Systematic Reviews 2010, Issue 1 Art. Noc. CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life' measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin'; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
pepper) cream in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Vitiligo priority 11	Whitton ME, Pinart M, Batchefor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for villigo. Cochrane Database of Systematic Reviews 2010, Issue 1 Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life' measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin'; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes

	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for Vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CO003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life' measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin'; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
catalase/dismutase in treating vitiligo?	Uncertainties identified in research recommendations	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*, cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
cream/ointment combined with exposure to natural sunlight (topical	Uncertainties identified in research recommendations	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for villigo. Cochrane Database of Systematic Reviews 2010, ISsue 1 Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Devices			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for villigo. Cochrane Database of Systematic Reviews 2010, Issue 1 Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects 'Primary outcomes
combined with other creams and ointments in treating vitiligo?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug	Devices		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for villigo. Cochrane Database of Systematic Reviews 2010, ISsue 1 Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		 Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; Iong- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
combined with other medicines taken		Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug	Physical therapies	Devices	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonzaft-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life* measured using a validated tool e.g. DLQ (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (al least two years follow-up); adverse effects *Primary outcomes

How effective is skin grafting in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Physical therapies	Surgery	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for Villigo. Cochrane Database of Systematic Reviews 2010, Issue 1, Art. Noc. C0003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of regimentation of vililiginous skin*; cessation of spread of vililiginous stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
mouth combined with exposure to	Uncertainties identified in research recommendations	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Environmental		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonard-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. Noc. C0003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life' measured using a validated tool e.g. DLO (Dermatology Quality of Life Index), CDLOI (Charlotogy Quality of Life Index), CDLOI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiligenous skin'; cessation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
How effective is the introduction of foreign bodies (such as intestinal worms) in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Unclassified		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonard-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. Noc. C0003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life' measured using a validated tool e.g. DLO (Dermatology Quality of Life Index), CDLOI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitilignous skin'; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Physical therapies		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. Noc. CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life' measured using a validated tool e.g. DLOI (Dermatology Quality of Life Index), CDLOI (Childrex), Skindex-29; Percentage of repigmentation of vitiligious skin'; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
How effective is UVA light therapy when combined with creams or ointments (e.g. khellin, lactic acid, steroid creams) in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. Noc. C0003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life" messured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiligonos skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
taken by mouth (e.g. phenylalanine,	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonard-Bee J, Gonz/lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. At. Noc. 20003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life' measured using a validated tool e.g. DLOI (Dermatology Quality of Life Index), CDLOI (Children's Dermatology Quality of Life Index), Skindex-29: Percentage of repigmentation of vitiliginous skin''; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects 'Primary outcomes

How effective is UVB light therapy when combined with creams or ontiments (e.g. steroid creams) in	Uncertainties identified from patients' questions Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age Any age	Physical therapies Drug	Devices	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD) Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Vitiligo priority 4 Vitiligo Ranked 4; Patient rank 0, HP 13	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for villigo. Cochrane Database of Systematic Reviews 2010, 10.1002/14651858.CD003263.pub4 Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for villigo. Cochrane Database of Systematic Reviews 2010, 10.1002/14651858.CD003263.pub4			Quality of life" measured using a validated tool e.g. DLQI (Dematology Quality of Life Index), CDLQI (Children's Dematology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects" Primary outcomes Quality of life" measured using a validated tool e.g. DLQI (Dematology Quality of Life Index), CDLQI (Children's Dematology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long-
											term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
when combined with medicines taken by mouth in treating vitiligo?	Uncertainties identified from clinicians' questions	systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for Villigo. Cochrane Database of Systematic Reviews 2010, Issue 1 Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo NCT01006421	Quality of life' measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of regimentation of vitiliginous skin'; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of regimentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
when combined with the needling technique in treating vitiligo?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leorardi-Bee J, Gorz/lez U, Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, ISsue 1 Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4			Quality of life" measured using a validated tool e.g. D.CU (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of villiginous skin"; cessation of spread of villigo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
interventions (such as counselling)	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Psychological therapy		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for villigo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4			Quality of life" measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
combined with UVB light therapy in	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug	Devices	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz'lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4			Safety
	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Devices		Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz'lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4			Safety

Vitiligo? How safe is UVA light therapy in treating vitiligo? How safe is UVB light therapy in treating vitiligo?	Uncertainties identified from patients' questions Uncertainties identified from patients' questions Uncertainties identified from patients' questions	important continuing uncertainties about treatment effects Reliable up-to-date systematic reviews have revealed uncertainties about treatment effects Reliable up-to-date systematic reviews	Any age Any age Any age	Drug Physical therapies Physical therapies			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Diseases (SPRUSD) Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Diseases (SPRUSD) Setting Priorities and Reducing Uncertainties for the Prevention and		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for villigo. Cochrane Database of Systematic Reviews 2010, 10.1002/14651858.CD003263.pub4 Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for villigo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4 Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for villigo. Cochrane Database of Systematic Reviews 2010, Interventions for villigo. Cochrane Database of Systematic Reviews 2010, Interventions for villigo. Cochrane Database of Systematic Reviews 2010,		Safety Safety Safety
Is pseudocatalase cream combined with brief exposure to UVB light as recommended, effective in treating vitiligo?	Uncertainties identified from patients' questions	uncertainties about treatment effects Reliable up-to-date systematic reviews have revealed uncertainties about treatment effects	Any age	Drug	Physical therapies	Devices	Treatment of Skin Disease (SPRUSD) Setting Priorities and Reducing Uncertainities for the Prevention and Treatment of Skin Disease (SPRUSD)	Vitiligo priority 10 Vitiligo Ranked 10; Patient rank 0; HP 0	Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4 Whitton ME; Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for Vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life* measured using a validated tool e.g. DLOI (Dermatology Quality of Life Index), CDLOI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vililigio or stabilisation of spread of vililigo or stabilisation of stread of vililigo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Devices			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for villigo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
Is UVB light therapy more effective in treating vitiligo when it first appears, rather than waiting until the disease has spread?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Physical therapies			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for Vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. Noc. C0003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life* measured using a validated tool e.g. DLQI (Chrildren's Dermatology Quality of Life Index), CDLQI (Chrildren's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitilgo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects 'Primary outcomes
What role might chemotherapy treatments play in treating vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for villigo. Cochrane Database of Systematic Reviews 2010, Issue 1 Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life* measured using a validated tool e.g. DLOI (Dermatology Quality of Life Index), CDLOI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitilignous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes

What role might gene therapy play in the treatment of vitiligo?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Vaccines and biologicals	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Ranked 5: Patient rank 2, Health P 4	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CC003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
What role might stem cell therapy play in treating vitiligo?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Surgery	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Vitiligo priority 12	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonzdraße J, Gorz/lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life" measured using a validated tool e.g. DLO (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitilignous skin"; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz'lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4		depigmentation
vitiligo: calcineurin inhibitors (e.g. tacrolimus, pimecrolimus) or light therapy?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for villigo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life* measured using a validated tool e.g. DLQI (Dematology Quality of Life lindex), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitilignous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects *Primary outcomes
vitiligo: calcineurin inhibitors (e.g.	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonzd'Ebe J, Gonz/lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4	Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis) NCT01082393	Quality of life' measured using a validated tool e.g. DLO (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitilignous skin'; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
vitiligo: calcineurin inhibitors (e.g.	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Vitiligo priority 7 Vitiligo Ranked 7; Patient rank 0, HP 2	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for villigo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life* measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes
Which treatment is more effective for vitiligo: calcineurin inhibitors (e.g. tacrofirus, pimerolimus) or vitamin D analogues (e.g. calcipotriol)?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life* measured using a validated tool e.g. DLQI (Chridfens's Dermatology Quality of Life Index), CDLQI (Chridfens's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitilignous skin*; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects "Primary outcomes

						-					
Which treatment is more effective for vitiligo: laser or other light therapy?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Physical therapies			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonz/Hez U, Bonz/Hez U, Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1 Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life' measured using a validated tool e.g. DLO (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vililiginous Skin'; cessation of spread of vililigo or stabilisation of the disease defined: long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects 'Primary outcomes
Which treatment is more effective for vitiligo: light therapy or calcineurin inhibitors (e.g. tacrolimus, pimecrolimus)?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug	Devices	Physical therapies	Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)	Vitiligo priority 3 Vitiligo Ranked 3; Patient Rank 0, HP 10	Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for villigo. Cochrane Database of Systematic Reviews 2010, Issue 1 Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life" measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitilignous skin'; cessation of spread of vitiligo or stabilisation of the disease defined: long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects 'Primary outcomes
Which treatment is more effective for vitiligo: melagenina or UV light?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life' measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitilignour skin'; cessation of spread of vitiligo or stabilisation of the disease defined: long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects 'Primary outcomes
Which treatment is more effective for vitiligo: psoralen taken by mouth or psoralen cream/ointment?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for villigo. Cochrane Database of Systematic Reviews 2010, ISsue 1 Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life' measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitilignous Skin'; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects 'Primary outcomes
Which treatment is more effective for vitiligo: steroid cream or a different oream that suppresses the immune system?	Uncertrainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchefor J, Lushey C, Leonardi-Bee J, Gonz?lez U, Interventions for villigo. Cochrane Database of Systematic Reviews 2010, ISsue 1 Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life" measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitiliginous skin'; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects 'Primary outcomes
Which treatment is more effective for vitiligo: steroid creams/ointments or light therapy?	identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Drug	Physical therapies	Devices	Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME. Pinart M. Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for villigo. Cochrane Database of Systematic Reviews 2010, ISsue 1 Art. No: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life' measured using a validated tool e.g. DLQI (Dermatology Quality of Life Index), CDLQI (Children's Dermatology Quality of Life Index), Skindex-29; Percentage of repigmentation of vitilignous skin'; cessation of spread of vitiligo or stabilisation of the disease defined; long- term permanence of repigmentation resulting from treatment (at least two years follow-up); adverse effects 'Primary outcomes
Which treatments are more effective for improving the quality of life of patients with vitiligo: psychological interventions or treatments to aid repigmentation?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Any age	Mixed or complex			Setting Priorities and Reducing Uncertainties for the Prevention and Treatment of Skin Disease (SPRUSD)		Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz?lez U. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub4		Quality of life